<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25096" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, MHC Class I</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Becar</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Becar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25096.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Major histocompatibility complex (MHC) class I is a diverse set of cell surface receptors expressed on all nucleated cells in the body and platelets. MHC&#x000a0;is also known as&#x000a0;human leukocyte antigen&#x000a0;(HLA), of which there are&#x000a0;3 subtypes: HLA-A, HLA-B, and HLA-C. These molecules play a vital role in the immune system recognizing self from nonself, presenting foreign antigens to other immune cells. HLA class I alleles are extremely polymorphic among the world population, which presents issues relating to human tissue transplants.<xref ref-type="bibr" rid="article-25096.r1">[1]</xref><xref ref-type="bibr" rid="article-25096.r2">[2]</xref></p>
      </sec>
      <sec id="article-25096.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>MHC class I cross-reactivity is often the mediator in transplant reactions. A host T-cell may bind the MHC molecule on the donor's grafted tissue and recognize the graft as nonself.&#x000a0;Subsequently, it mounts an immune attack on the graft via a cascade of immune cell activation. This type of reaction is labeled a T-cell&#x02013;mediated reaction. T-cell&#x02013;mediated reactions are responsible for acute transfusion reactions, with symptoms arising in days to weeks after transplant. The host may have also become sensitized via a previous transplant, blood transfusion, or pregnancy. The sensitization process resulting in anti&#x02013;HLA antibodies is called alloimmunization and is poorly understood. Anti&#x02013;HLA antibodies are responsible for hyperacute transfusion reactions, which arise minutes to hours after transfusion.<xref ref-type="bibr" rid="article-25096.r1">[1]</xref><xref ref-type="bibr" rid="article-25096.r3">[3]</xref><xref ref-type="bibr" rid="article-25096.r1">[1]</xref></p>
        <p>Before transplanting any hemopoietic precursors, such as stem cells or solid tissue transplants of kidneys or livers, a pretransplant crossmatch test is necessary to evaluate the reactivity of the recipient's HLA antibodies against the donor's HLA proteins.<xref ref-type="bibr" rid="article-25096.r4">[4]</xref>&#x000a0;HLA class I proteins are highly immunogenic. If the HLA types do not match,&#x000a0;there can be a hyperacute reaction in which the recipient's immune system recognizes the graft as foreign and signals the body's immune system to destroy the allograft.</p>
        <p>Another concern is the association of specific HLA alleles leading to a genetic predisposition to developing some disease conditions. Although&#x000a0;it is often unclear exactly how these HLA class I subtypes have implications in the pathogenesis of the disease, their presence may aid in diagnosing particular diseases. Further research is needed to discover how these alleles contribute to disease and any therapies that could prevent their action.</p>
      </sec>
      <sec id="article-25096.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>MHC class&#x000a0;I molecules are protein structures consisting of three alpha domains and a beta-two macroglobulin domain. The HLA class I gene is located on the chromosome, while beta-2 macroglobulin encoding is on chromosome 15.<xref ref-type="bibr" rid="article-25096.r5">[5]</xref>&#x000a0;The HLA class&#x000a0;I alleles are codominant expressed, and inheritance is via simple Mendelian inheritance patterns.<xref ref-type="bibr" rid="article-25096.r6">[6]</xref></p>
        <p>The alpha-1 and -2 domains are the binding cleft for various peptides, which are then presented to a T-cell receptor. One end of the alpha domain also serves as the binding site for an inhibitory receptor in natural killer (NK) cells. The beta-2 macroglobulin acts to stabilize the peptide binding.<xref ref-type="bibr" rid="article-25096.r5">[5]</xref>&#x000a0;The binding cleft of MHC class I tyrosine residues flank me and create closed ends that limit the peptide size; it can bind to around 8&#x000a0;to 10 amino acids. These amino acids are of cytosolic origin. Self or foreign cytosolic proteins are degraded via the proteasome and transported into the lumen of the endoplasmic reticulum. There, the peptides are loaded onto an MHC class&#x000a0;I via a chaperone protein named tapasin. The peptide-bound MHC class I is then transported to the cell&#x02019;s plasma membrane, presenting the peptide to CD8+ T-cell receptors.<xref ref-type="bibr" rid="article-25096.r7">[7]</xref></p>
      </sec>
      <sec id="article-25096.s4" sec-type="Function">
        <title>Function</title>
        <p>HLA class I functions as part of the adaptive immune system and plays a vital role in recognizing self from nonself and providing protection against viruses and tumors. In a healthy person, HLA class&#x000a0;I binds degraded cytosolic self-proteins and then transports these fragments to the cell membrane, where they present to CD8+ T lymphocytes. When the presented peptide is of foreign origin, such as one derived from a virus-infected cell, the CD8+ T cell eliminates the infected cell. MHC class&#x000a0;I&#x02013;presenting self-proteins also serve as an inhibitory signal to NK cells; this prevents NK killing from healthy cells.</p>
      </sec>
      <sec id="article-25096.s5" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>HLAs are identifiable via multiple detection methods.</p>
        <p>
<bold>Molecular Testing</bold>
</p>
        <p>
<bold>Sequence-specific primer polymerase chain reaction</bold>
</p>
        <p>Sequence-specific primer polymerase chain reaction (PCR) uses various primers complementary to specific HLA DNA sequences. The DNA is plated into a multiwell plate with different primers. If the DNA extracted from that cell is complementary to the primer, it&#x000a0;is&#x000a0;amplified, and the product can be run on a gel via electrophoresis. The band can be identified as a primer and matched to known candidate HLA alleles.<xref ref-type="bibr" rid="article-25096.r8">[8]</xref></p>
        <p>
<bold>Sequence-specific oligonucleotide probes</bold>
</p>
        <p>One way to detect the high polymorphism seen in these genes is via&#x000a0;PCR paired with sequence-specific oligonucleotides. This method involves amplifying the gene via PCR and then probing DNA with a fluorescent tag. The HLA type is determined using known HLA alleles as a reference, and that gene may undergo sequencing.<xref ref-type="bibr" rid="article-25096.r8">[8]</xref><xref ref-type="bibr" rid="article-25096.r9">[9]</xref><xref ref-type="bibr" rid="article-25096.r8">[8]</xref></p>
        <p>
<bold>Direct DNA sequencing</bold>
</p>
        <p>Another technique is to use Sanger sequencing or next-gen sequencing to sequence the entire gene of a specific HLA variant after amplification via PCR. Once the sequence is known, it can be compared to previously published HLA alleles.<xref ref-type="bibr" rid="article-25096.r8">[8]</xref></p>
        <p>
<bold>Serological Testing</bold>
</p>
        <p>Serological testing generally uses a recipient's lymphocytes obtained from their sera and incubated with anti&#x02013;sera-containing antibodies against various HLA class 1 subtypes. The solution is then incubated with rabbit sera, providing a source of complement; a dye is also added to identify dead cells. This assay progresses serially with different HLA antibodies put into each well of a tray. Eliminating those wells with a positive result allows for determining the HLA type. This method provides a relatively quick and easy way to determine general subtypes of HLA's present. Still, it does not offer an in-depth analysis of the true molecular identity of the HLAs. This method is less common today because of its inability to detect small changes in HLA types that may make an immunological difference and cause a transfusion reaction.<xref ref-type="bibr" rid="article-25096.r8">[8]</xref><xref ref-type="bibr" rid="article-25096.r10">[10]</xref><xref ref-type="bibr" rid="article-25096.r8">[8]</xref></p>
        <p>
<bold>Antibody Testing</bold>
</p>
        <p>Cytotoxic cell-based antibody testing can also effectively measure the recipient's risk of having a positive crossmatch. In this method, 30&#x000a0;to 40 donor cell lymphocytes are mixed with dye and complemented with the recipient's serum. Suppose the recipient's serum contains high enough HLA-specific antibodies against a particular donor. In that case,&#x000a0;the lymphocyte complement is activated, the cell will die, the dye will be taken up, and that well in the plate will be visually identifiable as a positive result. This test yields a value known as a percentage panel reactive antibody. Its result measures the recipient's risk of a positive crossmatch in a similar population of donors. This test does lack the ability to take race and different HLA frequencies in a population into account, weakening its value.<xref ref-type="bibr" rid="article-25096.r8">[8]</xref></p>
      </sec>
      <sec id="article-25096.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Transplant rejection remains one of the most clinically relevant issues surrounding the HLA class&#x000a0;I molecule. Identifying the donor and recipient&#x02019;s HLA status is imperative to prevent transplantation reactions. Continuing education on the different serological, molecular, and cellular tests available to clinicians and their proper use, and healthcare professionals must learn how to interpret them.</p>
        <p>
<bold>Spondylosis Ankylosis</bold>
</p>
        <p>Research has shown a strong correlation between <italic toggle="yes">HLA-B27</italic> and ankylosing spondylitis. Among those with the <italic toggle="yes">HLA-B27</italic> allele, 5% to 6% develop ankylosing spondylitis.<xref ref-type="bibr" rid="article-25096.r11">[11]</xref>&#x000a0;Ankylosing spondylitis is a seronegative spondyloarthropathy that leads to progressive spine and sacroiliac joint stiffness. This stiffness results from improper bone deposition, leading to fused vertebrae. The exact role of <italic toggle="yes">HLA-B27</italic> in AS is still unknown.<xref ref-type="bibr" rid="article-25096.r12">[12]</xref></p>
        <p>
<bold>Behcet Disease</bold>
</p>
        <p>Research has found the <italic toggle="yes">HLA-B51</italic> allele to be the greatest risk factor for developing Behcet disease. Behcet disease is an autoinflammatory condition resulting in normally immune-privileged sites such as the brain, eye, and joints infiltrating neutrophils. The link between the pathogenesis of Behcet disease and HLA B51 is still unclear. More research is needed to ascertain the true connection between the <italic toggle="yes">HLA-B21</italic> allele and Behcet disease. Researchers postulate that it could be due to antigen presentation to CD8+ cells or <italic toggle="yes">HLA-B51</italic>&#x02019;s interaction with NK receptor KIR3DL1.<xref ref-type="bibr" rid="article-25096.r13">[13]</xref></p>
        <p>
<bold>Psoriasis</bold>
</p>
        <p>Psoriasis, an autoimmune condition, is highly linked to specific HLA class I alleles, including&#x000a0;<italic toggle="yes">HLA-A01</italic>, <italic toggle="yes">HLA-A02</italic>,&#x000a0;<italic toggle="yes">HLA-B13</italic>,&#x000a0;<italic toggle="yes">HLA-B17</italic>,&#x000a0;<italic toggle="yes">HLA-B39</italic>,&#x000a0;<italic toggle="yes">HLA-B57</italic>,&#x000a0;<italic toggle="yes">HLA-Cw06</italic>, and&#x000a0;<italic toggle="yes">HLA-Cw07.&#x000a0;</italic>The role of HLA in psoriasis is currently unknown.<xref ref-type="bibr" rid="article-25096.r14">[14]</xref></p>
        <p>
<bold>Birdshot Chorioretinopathy</bold>
</p>
        <p>Birdshot chorioretinopathy, a form of posterior uveitis, correlates with <italic toggle="yes">HLA-A29</italic>, with 85% to 97.5% of those diagnosed carrying the allele.<xref ref-type="bibr" rid="article-25096.r15">[15]</xref></p>
        <p>
<bold>HIV</bold>
</p>
        <p><italic toggle="yes">HLA-B27</italic>, <italic toggle="yes">HLA-B51</italic>, <italic toggle="yes">HLA-C06</italic>, and <italic toggle="yes">HLA-B5701</italic> all confer protection against HIV infection. The reason appears to be that the peptides presented by these alleles are structurally resistant to mutation. Another idea is that those CD8-positive T cells that interact with these specific alleles have higher functionality in riding the body of HIV-infected cells.<xref ref-type="bibr" rid="article-25096.r15">[15]</xref></p>
      </sec>
      <sec id="article-25096.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25096&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25096">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25096/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25096">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25096.s8">
        <title>References</title>
        <ref id="article-25096.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tumer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <chapter-title>Genetics, Human Major Histocompatibility Complex (MHC)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30855806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nordquist</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jamil</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, HLA Antigens</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31536268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blume</surname>
                <given-names>OR</given-names>
              </name>
              <name>
                <surname>Yost</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes.</article-title>
            <source>J Transplant</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>201754</fpage>
            <pub-id pub-id-type="pmid">22545199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Poulton</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Poles</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Factors affecting HLA expression: A review.</article-title>
            <source>Int J Immunogenet</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-320</page-range>
            <pub-id pub-id-type="pmid">31183978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostyu</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Hannick</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Traweek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ghanayem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heilpern</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>HLA class I polymorphism: structure and function and still questions.</article-title>
            <source>Hum Immunol</source>
            <year>1997</year>
            <month>Sep</month>
            <day>15</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">9438190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandiedonck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The human Major Histocompatibility Complex as a paradigm in genomics research.</article-title>
            <source>Brief Funct Genomic Proteomic</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>379</fpage>
            <page-range>379-94</page-range>
            <pub-id pub-id-type="pmid">19468039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wieczorek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abualrous</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Sticht</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvaro-Benito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stolzenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>No&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>292</fpage>
            <pub-id pub-id-type="pmid">28367149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Althaf</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>El Kossi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halawa</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Human leukocyte antigen typing and crossmatch: A comprehensive review.</article-title>
            <source>World J Transplant</source>
            <year>2017</year>
            <month>Dec</month>
            <day>24</day>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>339</fpage>
            <page-range>339-348</page-range>
            <pub-id pub-id-type="pmid">29312863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wordsworth</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Techniques used to define human MHC antigens: polymerase chain reaction and oligonucleotide probes.</article-title>
            <source>Immunol Lett</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>1-2</issue>
            <fpage>37</fpage>
            <page-range>37-9</page-range>
            <pub-id pub-id-type="pmid">1916922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Techniques used to define human MHC antigens: serology.</article-title>
            <source>Immunol Lett</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>1-2</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">1916915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Wenker</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Quint</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Ankylosing Spondylitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">29261996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fejzi&#x00107;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eminovi&#x00107;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karamehi&#x00107;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x00160;ahovi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00160;i&#x00161;i&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suljevi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Association Between Human Leukocyte Antigen-B*27 and Pathogenesis in Seronegative Spondyloarthropathies in Federation of Bosnia and Herzegovina.</article-title>
            <source>Arch Rheumatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>166</fpage>
            <page-range>166-175</page-range>
            <pub-id pub-id-type="pmid">31497763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*51 the primary risk in Beh&#x000e7;et disease.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2014</year>
            <month>Jun</month>
            <day>17</day>
            <volume>111</volume>
            <issue>24</issue>
            <fpage>8706</fpage>
            <page-range>8706-7</page-range>
            <pub-id pub-id-type="pmid">24876276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umapathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pawar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khuperkar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Devaraj</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Khopkar</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Hla-a and hla-B alleles associated in psoriasis patients from mumbai, Western India.</article-title>
            <source>Indian J Dermatol</source>
            <year>2011</year>
            <season>Sep-Oct</season>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>497</fpage>
            <page-range>497-500</page-range>
            <pub-id pub-id-type="pmid">22121262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25096.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiorillo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Paladini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sorrentino</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>HLA Class I or Class II and Disease Association: Catch the Difference If You Can.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>1475</fpage>
            <pub-id pub-id-type="pmid">29163539</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
